31 research outputs found
Human organic anion transporter OAT1 is not responsible for glutathione transport but mediates transport of glutamate derivatives
Human organic anion transporter 2 is distinct from organic anion transporters 1 and 3 with respect to transport function
Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake
Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer
Differential interaction of dicarboxylates with human sodium-dicarboxylate cotransporter 3 and organic anion transporters 1 and 3
Male-Dominant Activation of Rat Renal Organic Anion Transporter 1 (Oat1) and 3 (Oat3) Expression by Transcription Factor BCL6
Renal and non-renal response of ABC and SLC transporters in chronic kidney disease
Introduction: The solute carrier (SLC) and the ATP-binding cassette (ABC) transporter superfamilies play essential roles in the disposition of small molecules (endogenous metabolites, uremic toxins, drugs) in the blood, kidney, liver, intestine, and other organs. In chronic kidney disease (CKD), the loss of renal function is associated with altered function of remote organs. As renal function declines, many molecules accumulate in the plasma. Many studies now support the view that ABC and SLC transporters as well as drug metabolizing enzymes (DMEs) in renal and non-renal tissues are directly or indirectly affected by the presence of various types of uremic toxins, including those derived from the gut microbiome; this can lead to aberrant inter-organ communication. Areas covered: Here, the expression, localization and/or function of various SLC and ABC transporters as well as DMEs in the kidney and other organs are discussed in the context of CKD and systemic pathophysiology. Expert opinion: According to the Remote Sensing and Signaling Theory (RSST), a transporter and DMEcentric network that optimizes local and systemic metabolism maintains homeostasis in the steady state and resets homeostasis following perturbations due to renal dysfunction. The implications of this view for pharmacotherapy of CKD are also discussed.Fil: Torres, Adriana Monica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmaceuticas. Departamento de Ciencias Fisiológicas. Area Farmacología; ArgentinaFil: Dnyanmote, Ankur V.. Dalhousie University Halifax; CanadáFil: Granados, Jeffry C.. University of California at San Diego; Estados UnidosFil: Nigam, Sanjay K.. University of California at San Diego; Estados Unido